Content area
Full Text
Presentation
OPERATOR: Hello, and welcome to the Guardant Health First Quarter 2023 Financial Results Call. My name is Lauren, and I will be coordinating your call today. (Operator Instructions)
I will now hand you over to your host, Alex Kleban, Vice President of Investor Relations, to begin. Alex, please go ahead.
ALEX KLEBAN: Thank you. Earlier today, Guardant Health released financial results for the quarter ended March 31, 2023. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer. Craig Eagle, Guardant's Chief Medical Officer, will join for Q&A.
Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This call will also include a discussion of non-GAAP financial measures to adjust and to exclude certain specified items.
Additional information regarding material risks and uncertainties as well as reconciliations to the most directly comparable GAAP financial measures are available in the press release Guardant issued today as well as in our Form 10-K and other filings with the SEC. Guardant disclaims any intention or obligation to update or revise financial projections and forward-looking statements whether because of new information, future events or otherwise. Information in this conference call is accurate only as of the live broadcast.
With that, I'd like to turn the call over to Helmy.
HELMY ELTOUKHY, CO-FOUNDER, CO-CEO & CHAIRMAN, GUARDANT HEALTH, INC.: Thanks, Alex. Good afternoon, and thank you for joining our order first quarter 2023 earnings call. I will start off today's call today for providing an update on our progress so far in 2023 and go into more detail on our progress in therapy selection and MRD. I will then turn the call over to AmirAli for an update on screening. And finally, Mike will provide a more detailed look at our financials and outlook for 2023.
At Guardant, we have built one of the fastest-growing platforms in diagnostics, coupled with what we believe is the most exciting pipeline in the industry to fuel long-term growth. Today, we are the market leader in therapy selection and technology...